[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Masue N, Hasegawa Y: [Giant prostate carcinoma treated effectively with endocrine therapy: case report]. Hinyokika Kiyo; 2007 Feb;53(2):133-5
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
  • Computed tomography (CT) and magnetic resonance imaging revealed a giant prostate tumor.
  • The histologic diagnosis was moderately differentiated adenocarcinoma of prostate.
  • Combined androgen blockade therapy was performed.
  • Four months later, CT showed that the tumor had decreased markedly in size, and the serum prostate specific antigen level was within normal range.
  • Hormone refractory prostate cancer was not found 1 year after the start of treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chlormadinone Acetate / therapeutic use. Goserelin / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged, 80 and over. Anilides / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Humans. Magnetic Resonance Imaging. Male. Naphthalenes / administration & dosage. Nitriles. Piperazines / administration & dosage. Prostate-Specific Antigen / blood. Tosyl Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Naphthalenes; 0 / Nitriles; 0 / Piperazines; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; 0SY050L61N / Chlormadinone Acetate; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen; R9PHW59SFN / naftopidil
  •  go-up   go-down


2. Kobayashi S, Tsukamoto T, Tohsaka A, Tohma T: [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports]. Hinyokika Kiyo; 2008 Jun;54(6):423-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].
  • The decrease of the level of serum prostate specific antigen (PSA) after discontinuation of estramustine phosphate (EMP) has rarely been reported.
  • He was diagnosed with prostate cancer with multiple bone metastases.
  • During the 3-year treatment with EMP, PSA decreased to the nadir of 0.7 ng/ml and gradually increased to 14 ng/ml.
  • Transurethral bladder biopsy and transrectal prostate biopsy were performed.
  • The diagnosis was moderately differentiated adenocarcinoma of the prostate that invaded to the bladder.
  • Computed tomography (CT) showed a lymph node metastasis.
  • The treatment was changed to EMP after PSA failure.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Estramustine / adverse effects. Prostatic Neoplasms / drug therapy. Substance Withdrawal Syndrome
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634439.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 35LT29625A / Estramustine
  • [Number-of-references] 8
  •  go-up   go-down


3. Morikawa H, Cho M, Takada S, Fujimoto K, Uemura H, Ozono S, Hirao Y, Natsume O: [A case of primary transitional cell carcinoma of the prostate]. Hinyokika Kiyo; 2003 Jun;49(6):357-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary transitional cell carcinoma of the prostate].
  • Prostate cancer was strongly suspected by transrectal examination with prostate specific antigen (PSA) elevated to 77.8 ng/ml.
  • Pathological diagnosis of prostate biopsy specimen was transitional cell carcinoma with grade 3 malignancy and negative staining for PSA.
  • However, immunostaining for PSA revealed that the cervical lymph node specimen resected before was moderately differentiated adenocarcinoma of prostate.
  • Endocrine therapy (goserelin acetate depot, bicalutamide) and systemic chemotherapy (methotrexate, epirubicin, cisplatin) were performed combined with irradiation to right ischium metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Fatal Outcome. Humans. Male. Prostate-Specific Antigen / blood. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894737.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 11
  •  go-up   go-down


Advertisement
4. Singh RP, Raina K, Sharma G, Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res; 2008 Dec 1;14(23):7773-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
  • PURPOSE: The chronic nature of prostate cancer growth and progression leading to metastasis provides a large window for intervention.
  • Herein, for the first time, we investigated the effect and associated mechanisms of silibinin phosphatidylcholine (silybin-phytosome) on established prostate tumors in transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
  • EXPERIMENTAL DESIGN: Twenty-week-old TRAMP male mice having palpable prostate tumor were fed with control or 0.5% and 1%, w/w, silybin-phytosome diets for 11 weeks and then sacrificed.
  • RESULTS: Dietary silibinin inhibited the growth of prostate tumors (up to 60%, P < 0.001) and suppressed tumor progression from prostatic intraepithelial neoplasia to differentiated adenocarcinoma and poorly differentiated adenocarcinoma, with a complete absence of poorly differentiated adenocarcinoma at higher doses.
  • Silibinin moderately inhibited tumor cell proliferation and induced apoptosis, but strongly suppressed tumor microvessel density (up to 60%, P < 0.001), vascular endothelial growth factor, and vascular endothelial growth factor receptor-2 expression.
  • CONCLUSIONS: Overall, silibinin treatment of TRAMP mice bearing prostate tumor inhibited tumor growth, progression, local invasion, and distant metastasis involving suppression of tumor angiogenesis and epithelial-mesenchymal transition.
  • These findings would have greater relevance for the ongoing phase II clinical trial with silibinin-phytosome in prostate cancer patients.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):403-10 [17574861.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):104-8 [18181052.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2043-50 [18339887.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):156-81 [18166163.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2567-74 [17916909.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5617-20 [11059749.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] BioDrugs. 2001;15(7):465-89 [11520257.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3063-9 [12036915.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Prostate. 2002 Sep 1;52(4):253-63 [12210485.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):525-32 [12479270.001]
  • [Cites] Urol Res. 2003 Feb;30(6):347-55 [12599013.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):502-4 [8864193.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:156-64 [9027613.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1920-9 [9581834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7490-5 [10377442.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1188-202 [15558015.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1053-69 [16205633.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):359-71 [16633338.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):436-42 [16637061.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):63-9 [16728325.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Invest New Drugs. 2007 Apr;25(2):139-46 [17077998.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):413-9 [17826663.001]
  • [CommentIn] Clin Cancer Res. 2008 Dec 1;14(23):7581-2 [19047081.001]
  • (PMID = 19047104.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102514-05; United States / NCI NIH HHS / CA / R01 CA102514; United States / NCI NIH HHS / CA / R01 CA102514-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Silymarin; 0 / Vimentin; 0 / silybin-phytosome; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS82719; NLM/ PMC2639624
  •  go-up   go-down


5. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S: Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res; 2007 Jun 15;67(12):5789-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
  • Antiangiogenic therapy is a promising alternative for prostate cancer growth and metastasis and holds great promise as an adjuvant therapy.
  • The present study evaluated the potential of stable expression of angiostatin and endostatin before the onset of neoplasia and during the early and late stages of prostate cancer progression in transgenic adenocarcinoma of mouse prostate (TRAMP) mice.
  • The effects of therapy were determined by sacrificing groups of treated mice at defined stages of tumor progression and following cohorts of similarly treated mice for long-term survival.
  • Results indicated remarkable survival after recombinant adeno-associated virus-(E+A) therapy only when the treatment was given at an earlier time, before the onset of high-grade neoplasia, compared with treatment given for invasive cancer.
  • Interestingly, early-stage antiangiogenic therapy arrested the progression of moderately differentiated carcinoma to poorly differentiated state and distant metastasis.
  • Immunohistochemical analysis of the prostate from treated mice indicated significantly lower endothelial cell proliferation and increased tumor cell apoptosis.
  • Vascular endothelial growth factor receptor (VEGFR)-2 expression was significantly down-regulated in tumor endothelium after treatment but not VEGFR-1.
  • Analysis of the neuroendocrine marker synaptophysin expression indicated that antiangiogenic therapy given at an early-stage disease reduced neuroendocrine transition of the epithelial tumors.
  • These studies indicate that stable endostatin and angiostatin gene therapy may be more effective for minimally invasive tumors rather than advanced-stage disease.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / administration & dosage. Angiostatins / administration & dosage. Endostatins / administration & dosage. Prostatic Neoplasms / therapy
  • [MeSH-minor] Adenoviridae / genetics. Animals. Disease Models, Animal. Enzyme-Linked Immunosorbent Assay. Genetic Therapy / methods. Genetic Vectors. Immunohistochemistry. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Receptors, Vascular Endothelial Growth Factor / drug effects. Receptors, Vascular Endothelial Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Synaptophysin / drug effects. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575146.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA98817
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 0 / Synaptophysin; 86090-08-6 / Angiostatins; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


6. Hayakawa K, Matsumoto M, Aoyagi T, Miyaji K, Hata M: Prostate cancer with multiple lung metastases in a hemodialysis patient. Int J Urol; 2000 Dec;7(12):464-6
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer with multiple lung metastases in a hemodialysis patient.
  • In hemodialysis patients, few cases of prostate cancer have been reported until recently.
  • We present a case of prostate cancer with multiple lung metastases in a chronic hemodialysis patient.
  • Serum prostate tumor markers were highly elevated although his plasma testosterone level was within the normal range.
  • A transrectal needle prostate biopsy confirmed a histologic diagnosis of moderately differentiated adenocarcinoma.
  • Androgen blockade therapy was very effective as evidenced by a quick decrease of serum tumor markers.
  • The follow-up computed tomography scan of the chest performed 3 months later showed a complete disappearance of the coin lesions.
  • The early detection of prostate cancer in hemodialysis patients is difficult because of a lack of urologic symptoms, which indicate the importance of periodic screening by serum tumor markers.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Lung Neoplasms / secondary. Prostatic Neoplasms / pathology. Renal Dialysis
  • [MeSH-minor] Aged. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Drug Therapy, Combination. Flutamide / therapeutic use. Goserelin / therapeutic use. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11168686.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0F65R8P09N / Goserelin; 76W6J0943E / Flutamide
  •  go-up   go-down


7. Chin K, Fujimura M, Sekit N, Mikami K, Kamijima S, Suzuki H, Ichikawa T: [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma]. Nihon Hinyokika Gakkai Zasshi; 2009 Nov;100(7):698-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma].
  • Esophagogastroduodenoscopy revealed a huge ulcer in the stomach, and based on biopsy findings, he was pathologically diagnosed as having diffuse large B-cell type malignant lymphoma.
  • Histological findings revealed diffuse large B-cell type malignant lymphoma and moderately differentiated adenocarcinoma of the prostate.
  • The patient achieved complete response after eight cycles of combination chemotherapy with rituximab cyclophosphamide, adriamycin, vincristine and predonisolone.
  • At the same time of chemotherapy, androgen deprivation therapy was initiated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasms, Multiple Primary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Remission Induction. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999135.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 12
  •  go-up   go-down


8. Colonias A, Farinash L, Miller L, Jones S, Medich DS, Greenberg L, Miller R, Parda DS: Multidisciplinary treatment of synchronous primary rectal and prostate cancers. Nat Clin Pract Oncol; 2005 May;2(5):271-4; quiz 1 p following 274
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment of synchronous primary rectal and prostate cancers.
  • A digital rectal examination revealed a 3 cm distal, midrectal mass.
  • Laboratory tests showed an elevated serum prostate-specific antigen of 32 ng/ml but other physical and medical examinations were unremarkable.
  • INVESTIGATIONS: Digital rectal examination, colonoscopy, rectal mass biopsy, endorectal ultrasound, transrectal ultrasound-guided prostate biopsy, CT scan and MRI.
  • DIAGNOSIS: Clinical stage III (T3N1M0), moderately differentiated adenocarcinoma of the rectum and clinical stage II (T1cN0M0) adenocarcinoma of the prostate.
  • MANAGEMENT: Intensity-modulated radiation therapy, chemoradiation, chemotherapy, hormone therapy and surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Gastrointestinal Hemorrhage / etiology. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264963.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


9. Kurita M, Kato Y, Tamura Y, Suzuki K, Yamanaka H: [A case of prostate cancer treated with combined androgen-blockade]. Gan To Kagaku Ryoho; 2000 Feb;27(2):307-10
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostate cancer treated with combined androgen-blockade].
  • A digital rectal examination revealed an enlarged, elastic, and hard prostate with an irregular surface.
  • Prostatic biopsy was done and the pathological diagnosis was moderately differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / administration & dosage. Antineoplastic Agents / administration & dosage. Diethylstilbestrol / analogs & derivatives. Flutamide / administration & dosage. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700907.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents; 731DCA35BT / Diethylstilbestrol; 76W6J0943E / Flutamide; A0E0NMA80F / fosfestrol
  •  go-up   go-down


10. Willman JH, Holden JA: Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate. Prostate; 2000 Mar 1;42(4):280-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
  • BACKGROUND: The DNA topoisomerase II-alpha (topo II-alpha)-targeting drug etoposide was recently shown to be an active agent in the combined chemotherapy of hormone-insensitive prostatic carcinoma.
  • Much experimental data indicate that cells sensitive to topo II-targeting chemotherapeutic drugs are rapidly proliferating and show elevated topo II expression.
  • There is little information concerning topo II expression in lesions of the prostate.
  • RESULTS: The average topo II-alpha index for well-differentiated prostatic adenocarcinomas (Gleason scores 2-4) was 1.5 +/- 0.9; for moderately differentiated tumors (Gleason scores 5-7), 3.1 +/- 2.4; and for poorly differentiated tumors (Gleason scores 8-10), 6.7 +/- 5.5.
  • The average topo II-alpha index of 2.3 (range, 0-8.6) for high-grade prostatic intraepithelial neoplasia was intermediate between the invasive tumors and benign prostate.
  • CONCLUSIONS: Topo II-alpha expression in carcinoma of the prostate correlates with Gleason score.
  • The carcinomas with the highest expression of enzyme are more poorly differentiated and have the highest Gleason scores.
  • [MeSH-major] Adenocarcinoma / enzymology. DNA Topoisomerases, Type II / analysis. Isoenzymes / analysis. Prostate / enzymology. Prostatic Hyperplasia / enzymology. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10679757.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Isoenzymes; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


11. Sato N, Kotake T, Masai M, Sakai S, Ito H: [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue]. Hinyokika Kiyo; 2000 Jan;46(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue].
  • To investigate whether chlormadinone acetate (CMA) could prevent the flare-up phenomenon induced by a luteinizing hormone-releasing hormone analogue (LH-RHa), we treated 4 cases of stage C and 17 cases of stage D prostate cancer with CMA for 4 weeks and CMA plus monthly injection of LH-RHa for following 24 weeks.
  • Serum LH, testosterone, and prostate-specific antigen (PSA) levels were closely monitored before and 3 days, 1-, 2-, and 4-weeks after LH-RHa injection.
  • Out of 21 cases, 3 cases (14%) consisting of 2 poorly and 1 moderately differentiated adenocarcinoma showed increased serum PSA levels 1 week after LH-RHa injection in spite of suppressed serum testosterone levels.
  • The objective response of these 2 poorly differentiated cases was progressive disease at 24 weeks.
  • CMA seemed to be capable of preventing flare-up phenomenon in advanced prostate cancer.
  • [MeSH-major] Acute-Phase Reaction / prevention & control. Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / adverse effects. Chlormadinone Acetate / administration & dosage. Prostatic Neoplasms / drug therapy. Triptorelin Pamoate / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Drug Therapy, Combination. Humans. Luteinizing Hormone / blood. Male. Neoplasm Staging. Prostate-Specific Antigen / blood. Testosterone / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10723656.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0SY050L61N / Chlormadinone Acetate; 3XMK78S47O / Testosterone; 57773-63-4 / Triptorelin Pamoate; 9002-67-9 / Luteinizing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


12. Sakura M, Tsukamoto T, Yonese J, Nakaishi M, Maezawa T, Takimoto K, Fukui I: [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine]. Nihon Hinyokika Gakkai Zasshi; 2003 May;94(4):529-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
  • A 74-year-old man was referred to our clinic for the work-up of digitally hard and irregularly surfaced prostate and elevated serum prostate-specific antigen (PSA).
  • He had a history of taking an androgenic medicine containing methyl-testosterone 2 to 3 times a week for 2 year and 6 months.
  • Transrectal sextant prostatic biopsy revealed moderately differentiated adenocarcinoma (Gleason score: 3 + 4) in 6 of 6 specimens and CT scan of the abdomen showed an enlarged obturator lymph-node (15 mm), resulting in the diagnosis of stage D1 (T3aN1M0) prostate cancer.
  • Indeed, serum PSA decreased to 0.09 ng/ml and the right obturator node was markedly reduced by the hormone treatment.
  • After the neoadjuvant therapy of 6 months duration, radical prostatectomy and limited pelvic lymph node dissection was carried out.
  • Histologically, viable cancer cells were not found in any of resected lymph nodes, but they remained in bilateral lobes of the prostate (pT2bN0).
  • The histological effect of the neoadjuvant hormone therapy according to General rule for Clinical and Pathological Studies on Prostate Cancer (3rd ed.) was grade 2.
  • The patient has been well with undetectable PSA and no evidence of clinical failure for more than 12 months, though serum testosterone level recovered to near normal (288 ng/dl) 8 months after the cessation of the hormone treatment following the operation.
  • Combination androgen blockade or non-steroidal anti-androgen agent appears to be effective for the treatment of prostatic cancer patients who takes exogenous androgenic medicine, even with a suppressed low serum testosterone level.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anilides / administration & dosage. Methyltestosterone / administration & dosage. Prostatic Neoplasms / drug therapy. Testosterone / blood
  • [MeSH-minor] Aged. Androgen Antagonists / administration & dosage. Gonadotropin-Releasing Hormone / agonists. Humans. Male. Nitriles. Prostate-Specific Antigen / blood. Prostatectomy. Tosyl Compounds

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. 17-METHYLTESTOSTERONE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795169.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen; V9EFU16ZIF / Methyltestosterone
  •  go-up   go-down


13. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B: Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology; 2004 Feb;63(2):259-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
  • OBJECTIVES: To determine whether supplemental amounts of soy isoflavone (genistein-rich extract) would lower prostate-specific antigen (PSA) levels more than 50% in patients with prostate cancer (CaP).
  • An open-label pilot study was conducted for 6 months in which the patients took capsules containing the genistein-rich extract three times daily by mouth.
  • The subjects were in one of five groups: after radical retropubic prostatectomy (n = 9), after radiotherapy (n = 17), after both radical retropubic prostatectomy and radiotherapy (n = 6), off-cycle during hormonal therapy (intermittent hormones; n = 14), or active surveillance (n = 16).
  • The primary endpoint for the trial was a 50% reduction in the PSA level at 6 months compared with before treatment.
  • All 8 patients with lower PSA levels at 6 months were in the active surveillance (watchful waiting) treatment subgroup.
  • In the 9 patients with a partial response, 6 had pathologic findings that were moderately differentiated, 2 had well-differentiated findings, and 1 had poorly differentiated findings.
  • CONCLUSIONS: A genistein-rich extract as the sole treatment for CaP did not reduce PSA levels by 50% or more in 51 of 52 subjects.
  • Thus, it does not appear to be an effective treatment for CaP when given alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Biomarkers, Tumor / blood. Enzyme Inhibitors / therapeutic use. Genistein / therapeutic use. Neoplasm Proteins / blood. Phytotherapy. Plant Extracts / therapeutic use. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Soybeans / chemistry
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Combined Modality Therapy. Disease Progression. Drugs, Chinese Herbal / therapeutic use. Follow-Up Studies. Humans. Male. Middle Aged. Pilot Projects. Prostatectomy. Protein-Tyrosine Kinases / antagonists & inhibitors. Reishi / chemistry. Testosterone / blood. Treatment Failure


14. Segawa N, Abe H, Nishida T, Katsuoka Y: [A case of prostatic cancer discovered from lung metastatic lesions]. Hinyokika Kiyo; 2006 Feb;52(2):147-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Palpation of the prostate disclosed enlargement to hen's egg size with an irregular surface and indurations bilaterally.
  • Transrectal sextant needle biopsy of the prostate was performed, revealing moderately differentiated adenocarcinoma.
  • Computed tomography (CT) scan and bone scintigraphy showed intrapelvic lymphnode adenopathy and metastasis to the right pubic bone.
  • Under a diagnosis of stage D2 prostate cancer, we initiated endocrine therapy (luteinizing hormone-releasing hormone analogue depot every 4 weeks and bicalutamide).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Hormonal / administration & dosage. Lung Neoplasms / secondary. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Anilides / administration & dosage. Drug Administration Schedule. Humans. Leuprolide / administration & dosage. Male. Neoplasm Staging. Nitriles. Tomography, X-Ray Computed. Tosyl Compounds


15. Tokumitsu M, Inada F, Kitahara K, Kawakami N, Masui N, Ishida H, Ishida H, Saga Y, Hashimoto H, Yachiku S: [Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report]. Hinyokika Kiyo; 2001 Jan;47(1):59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report].
  • Prostatic cancer is rarely diagnosed by detection of lung metastases.
  • We report a case of prostatic cancer in a 73-year-old man detected by abnormalities in chest X-ray and serum prostate specific antigen (PSA) level.
  • A second prostatic biopsy and whole-body examination were performed, and he was diagnosed with moderately differentiated prostatic adenocarcinoma with multiple lung metastases.
  • Complete androgen blockade therapy was performed immediately.
  • Two months after the beginning of treatment, PSA level was normalized and the multiple lung metastases had completely disappeared.
  • There has been no evidence of recurrence or PSA relapse 24 months after detection of the prostatic cancer.
  • This is the 26th case of prostatic cancer diagnosed in Japan following detection of multiple lung metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Androgen Antagonists / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Flutamide / administration & dosage. Goserelin / administration & dosage. Lung Neoplasms / secondary. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Therapy, Combination. Humans. Male. Prostate-Specific Antigen / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235226.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0F65R8P09N / Goserelin; 76W6J0943E / Flutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 10
  •  go-up   go-down






Advertisement